KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medpace Holdings (MEDP) EPS (Weighted Average and Diluted) (2016 - 2026)

Medpace Holdings filings provide 12 years of EPS (Weighted Average and Diluted) readings, the most recent being $4.28 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 16.62% to $4.28 in Q1 2026 year-over-year; TTM through Mar 2026 was $15.88, a 21.22% increase, with the full-year FY2025 number at $15.28, up 20.98% from a year prior.
  • EPS (Weighted Average and Diluted) hit $4.28 in Q1 2026 for Medpace Holdings, down from $4.64 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $4.64 in Q4 2025 to a low of $1.46 in Q2 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $2.75 (2024), compared with a mean of $2.84.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 59.09% in 2022 and later grew 8.29% in 2023.
  • Medpace Holdings' EPS (Weighted Average and Diluted) stood at $2.1 in 2022, then grew by 17.14% to $2.46 in 2023, then skyrocketed by 49.19% to $3.67 in 2024, then increased by 26.43% to $4.64 in 2025, then dropped by 7.76% to $4.28 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were $4.28 (Q1 2026), $4.64 (Q4 2025), and $3.86 (Q3 2025) per Business Quant data.